Minerva neurosciences, inc. (NERV)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-68,507

-72,183

-55,468

-53,527

-53,580

-50,171

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-33,685

-31,045

-30,080

-27,596

-28,992

-27,081

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Depreciation and amortization

17

17

17

17

17

17

14

13

12

11

12

14

15

16

17

17

11

17

16

38

43

33

0

0

0

Amortization of debt discount recorded as interest expense

-

-

-

-

-

38

73

119

163

206

247

285

320

347

371

417

404

377

277

149

1,745

1,952

0

0

0

Accretion of marketable securities premium

586

764

688

537

308

119

195

228

237

185

83

28

-40

-102

0

0

0

-

-

-

-

-

-

-

-

Amortization of right-of-use assets

147

144

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

8,909

9,173

8,912

8,952

8,530

8,182

7,531

6,503

5,837

5,033

4,788

4,489

4,091

3,571

3,249

2,942

2,656

2,202

3,757

4,031

18,000

17,966

0

0

0

Unrealized foreign exchange gain

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

0

0

0

Changes in operating assets and liabilities
Prepaid expenses and other current assets

-202

-723

-2,307

-1,760

-3,174

621

2,655

2,643

3,277

306

152

118

167

-372

0

0

0

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

0

Accounts payable

-22

517

4,455

1,631

200

364

-628

-97

-450

-32

670

667

2,051

107

98

175

327

718

-197

-938

-563

368

0

0

0

Accrued expenses and other current liabilities

215

2,329

1,402

2,174

1,328

369

973

1,036

719

624

1,041

-177

-1,428

-1,708

-1,243

370

1,430

879

1,374

-970

198

112

0

0

0

Operating lease liabilities, current

22

37

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued collaborative expenses

-

-

-

-

-

-

-

-

-

-2,547

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued collaborative expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Other noncurrent liabilities

-

-

-

-

-

-0

0

0

0

-

-

-

-

-

-

-

-

-7

0

0

0

-

-

-

-

Operating lease liabilities, noncurrent

-178

-172

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-43,034

-43,432

-39,051

-39,514

-40,610

-41,941

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Proceeds from the maturity and redemption of marketable securities

87,079

75,179

71,145

64,800

79,901

110,151

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in business combination

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,167

0

0

0

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

44

0

0

0

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-25,683

-25,687

-23,362

-24,433

-25,409

-24,269

-22,683

-44,117

-39,630

-35,960

0

0

0

Proceeds from the maturity and redemption of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

17,818

0

0

0

-

-

-

-

-

-

-

-

Purchase of marketable securities

45,414

61,094

82,174

65,911

52,278

40,661

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided (used in) by investing activities

41,664

14,084

-11,029

-1,111

27,622

69,489

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-6,702

17,818

21,868

14,320

-10,281

-18,329

-22,426

-23,288

-85

1,087

0

0

0

Proceeds from loans

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Costs paid in connection with public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,159

0

0

0

Proceeds from sales of common stock in private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

999

999

999

999

30,999

0

0

0

-

-

-

-

Costs paid in connection with private placements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,466

0

0

0

-

-

-

-

Proceeds from exercise of common stock warrants

-

-

-

-

-

-

-

-

-

9,356

10,526

10,526

15,204

23,392

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

797

524

0

0

0

-

-

-

-

1,130

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,000

0

0

0

-

-

-

-

Costs paid in connection with notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

195

0

0

0

-

-

-

-

Repayments of notes payable

-

-

-

-

-

4,000

5,268

5,115

5,026

4,938

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

797

524

690

-217

-1,529

-3,344

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-571

-28,822

-49,390

-40,843

-14,517

24,203

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash, cash equivalents and restricted cash
Incurred but unpaid private/public placement costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

92

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

656

691

705

705

705

616

0

0

0

-

-

-

-

Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets
Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

68,696

75,016

66,934

-17,378

-4,261

-6,802

21,255

50,059

16,727

0

0

0

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

66,458

76,566

76,511

77,047

18,311

38,337

38,307

88,660

89,775

51,600

0

0

0

Net increase (decrease) in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued as consideration for business combination

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,541

0

0

0

Accrued expenses and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

321

0

0

0

ProteoSys milestone payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

681

0

0

0

Deferred tax liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,970

0

0

0

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

42

0

0

0

Equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28

0

0

0

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,200

0

0

0

Goodwill

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,076

0

0

0

Cash acquired in business merger

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,167

0

0

0

Incurred but unpaid private placement costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Incurred but unpaid public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0